Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Control Bionics Ltd. ( (AU:CBL) ) has provided an announcement.
Control Bionics Limited has successfully raised approximately $1.46 million through a Non-Renounceable Rights Issue, with plans to issue additional shares to cover the shortfall. This capital injection provides the company with financial flexibility to pursue its business objectives, enhancing its position in the medical device industry and potentially benefiting stakeholders by supporting growth and innovation.
More about Control Bionics Ltd.
Control Bionics is a medical device company that develops technology to assist patients with communication impairments due to conditions like Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Their core product, the NeuroNode, is a wireless wearable device that detects brain signals to enable communication through computers. They also offer the DROVE autonomous wheelchair module and are commercializing the NeuroStrip for new markets such as health diagnostics and sports performance. The company operates in North America, Australia, Singapore, and Japan.
Average Trading Volume: 137,709
Technical Sentiment Signal: Sell
Current Market Cap: A$12.02M
Find detailed analytics on CBL stock on TipRanks’ Stock Analysis page.